Related Experiment Video
Updated: Aug 20, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
BMS-310705 Bristol-Myers Squibb/GBF
1Department of Molecular Biology and Functional Genomics, Stockholm University, SE-106 91 Stockholm, Sweden. ada.kolman@telia.com
Abstract:
Bristol-Myers Squibb, in collaboration with the German Research Centre for Biotechnology, is developing BMS-310705, an epothilone analog, for the potential treatment of cancer. By April 2002, phase I trials of BMS-310705 were underway.
More Related Videos
08:24Stereotactic Intracranial Implantation of Glioblastoma Patient-derived Xenograft Cell Lines in Mice
Published on: February 27, 2026
10:52Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme
Published on: September 25, 2012